<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983199</url>
  </required_header>
  <id_info>
    <org_study_id>21-5322</org_study_id>
    <nct_id>NCT04983199</nct_id>
  </id_info>
  <brief_title>Patient Reported Outcomes/Metrics Program Trial</brief_title>
  <acronym>PROMPT</acronym>
  <official_title>Patient Reported Outcomes/Metrics Program Trial - Palliative Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to investigate if it is feasible to recruit 100 patients&#xD;
      receiving radiotherapy (RT) to metastatic disease to wear Hexoskin and if Hexoskin will&#xD;
      facilitate the monitoring, detection and early treatment of RT-related side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiotherapy is an important adjunct in the interdisciplinary care of the palliative patient&#xD;
      population, providing the potential for improved quality of life and symptom control, often&#xD;
      translating into improved well-being, function and mobility. Changes in pain and QOL are&#xD;
      frequently measured subjectively using patient-reported questionnaires. Objective measures&#xD;
      such as respiratory rate, pulse rate, activity level and sleep duration and quality, may&#xD;
      complement the currently available tools. Such tools may lead to better evaluation of the&#xD;
      effects of palliative RT with real-time detection of potential complications and toxicity and&#xD;
      the acute need for analgesic adjustments that can result from successful palliative RT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patient accrual</measure>
    <time_frame>Over 12 months</time_frame>
    <description>Feasibility of accruing 100 patients to the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of radiotherapy related adverse events</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Frequency of grade 2 or above radiotherapy related adverse events with extended monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality Adjusted Life Years (QALY)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Perform economic and health technology assessment using EuroQol-5 Dimension-5 Level (EQ-5D-5L) health questionnaire. (100 is the best health a patient can imagine while 0 is the worst health a patient can imgaine.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (QOL)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Perform Health Related Quality of Life using EORTC QLQ-C30 and rate electronic survey completion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Trial Refusals</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Evaluate reasons for trial refusal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete follow-ups</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Rate of completed follow-ups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient experience and satisfaction</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Measure patient experience and satisfaction using mobile app (Zamplo) and Hexoskin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Adherence</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Patient adherence to using the Hexoskin Medical System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hexoskin data collection rates</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Feasibility of data collection using the Hexoskin Medical System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) survey completion</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Rate of Quality of Life (QOL) survey completion on mobile app (Zamplo)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of participants</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Overall survival time is calculated from study enrollment to date of death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize adverse event profile</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Characterize adverse event profile of various radiotherapy regimens given for metastases</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Palliative</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hexoskin Medical System</intervention_name>
    <description>Hexoskin is a smart shirt that can detect heart rates, lung function and physical activity of patients before and after radiotherapy.</description>
    <other_name>Hexoskin Smart Shirt</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients planned for palliative radiotherapy to metastatic disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Planned to receive palliative radiotherapy for pain&#xD;
&#xD;
          -  Known cancer diagnosis&#xD;
&#xD;
          -  Able to wear Hexoskin Medical Shirt&#xD;
&#xD;
          -  Ability to use and populate the mobile app (Zamplo) with or without assistance&#xD;
&#xD;
          -  ECOG: 0-3&#xD;
&#xD;
          -  Willing to provide a list of analgesic (pain relief) medication&#xD;
&#xD;
          -  Willing to complete questionnaires&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving whole brain radiotherapy&#xD;
&#xD;
          -  Major cognitive or psychiatric impairments&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Allergies to: polyester, synthetic fibers&#xD;
&#xD;
          -  Patients with pacemakers or implantable cardioverter-defibrillator (ICD)&#xD;
&#xD;
          -  Patients on a Holter Monitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aisling Barry</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network--Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aisling Barry</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>3972</phone_ext>
    <email>aisling.barry@rmp.uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Phillip Wong</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>6889</phone_ext>
    <email>philip.wong@rmp.uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

